ncx

NCX899 shows inhibitory activity against angiotensin-converting enzyme (ACE) activity.

NCX1022 is a NO-releasing derivative of Hydrocortisone. It is the most widely used anti-inflammatory drug for the treatment of skin inflammation.

COX-2 expression inhibitor

NCX-278 is a ROCK inhibitor and NO-donating anti-glaucoma agent.

NCX-274 is a ROCK inhibitor and NO-donating anti-glaucoma agent

ORM-10103 is a novel potent and selective inhibitor of the Na+/Ca2+ exchanger (NCX).ORM-10103 inhibited NCX currents with estimated IC50 values of 55 and 67 nM at -80 and 20 mV, respectively, and reduced early and delayed postdepolarization in canine hearts.

ORM-10962 is a potent and highly selective inhibitor of the sodium-calcium exchanger (NCX), with IC50 values of 67 nM for reverse mode inhibition and 55 nM for forward mode inhibition.

SEA0400 is a selective inhibitor of the Na+/Ca2+ exchanger.

NO-prednisolone (NCX-1015) is a compound that effectively stimulates the production of IL-10 in vivo. It is a Prednisolone derivative that releases nitric oxide (NO).

Nitroaspirin (NCX 4016) is a nitric oxide donor and a nitro-derivative of Aspirin that inhibits cyclooxygenase. It induces cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells by down-regulating EGFR/PI3K/STAT3 signaling and modulating Bcl-2 family proteins. Additionally, Nitroaspirin possesses antithrombotic and antiplatelet properties and acts as a direct and irreversible inhibitor of COX-1.

Latanoprostene bunod (LBN) is nitric oxide (NO)-donating prostaglandin F2a analog and is a topical ophthalmic therapeutic. It is used for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT).

Sildenafil nitrate is a selective inhibitor of PDE5 (type 5 cGMP phosphodiesterase) which catalyzes the hydrolysis of 3',5'-cyclic guanosine monophosphate (cGMP).

PU-H71 hydrate is a potent inhibitor of heat shock protein 90 (Hsp90).

AM0216 is a novel highly potent inhibitor of NF-κB inducing Kinase (NIK).

TPI-1020 is a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide. It exhibits a concentration-dependent bronchodilatory effect mediated by released NO through a cGMP-dependent pathway. Studies suggest that TPI-1020 combines corticosteroid activity with NO release, potentially benefiting the treatment of acute bronchoconstriction events in asthma and allowing for a reduced dose of inhaled beta(2)-adrenoceptor agonists.

NCX 1000, a liver-specific NO donor compound, is derived from ursodeoxycholic acid (UDCA).

NCX1-IN-1 (Compound 6) is an inhibitor of the Na+/Ca2+ exchanger (NCX).

cyclooxygenase (COX)-inhibiting nitric oxide (NO) donor

NCX-6560 is a novel NO-releasing derivative of atorvastatin, with those of atorvastatin. NCX-6560 inhibits cholesterol biosynthesis in rat smooth muscle cells with an IC50 of 1.9 μM.

SN 6 (SN6) is a selective Na+/Ca2+ exchanger (NCX) inhibitor (IC50s of NCX1: 2.9 μM , NCX2: 16 μM ,NCX3: 8.6 μM)

SCH 546738 is an orally available, selective and potent CXCR3 antagonist that attenuates the development of autoimmune diseases and delays graft rejection.

YM-244769 dihydrochloride is an effective inhibitor of Na+/Ca2+ exchange 3 (NCX3) with an IC50 of 18 nM. YM-244769 dihydrochloride has efficient protective effects on neurons and kidneys.

NBI-74330 is a high-affinity CXCR3 antagonist that inhibits the binding of CXCR3 to its ligands CXCL10 and CXCL11, reduces the formation of atherosclerotic plaques in LDL receptor-deficient mice, and decreases the migration of CD4+ T cells and macrophages to the peritoneum.

YM-244769 (3-Pyridinecarboxamide, N-[(3-aminophenyl)methyl]-6-[4-[(3-fluorophenyl)methoxy]phenoxy]-) is an effective inhibitor of Na+/Ca2+ exchange 3 (NCX3) with an IC50 of 18 nM. YM-244769 has efficient protective effects on neurons and kidneys.